A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 615
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DOAC
Long Form : direct oral anticoagulant
No. Year Title Co-occurring Abbreviation
2021 A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. ---
2021 Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. AF, MI, VTE
2021 Adverse outcomes associated with inappropriate direct oral anticoagulant starter pack prescription among patients with atrial fibrillation: a retrospective claims-based study. AF, ED, VTE
2021 American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. ASH, GRADE, LMWH, VTE
2021 An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug. COVID-19, PE
2021 Anticoagulation for newly diagnosed atrial fibrillation and 90-day rates of stroke and bleeding. TIA
2021 Anticoagulation Management In Hemodialysis Patients With Atrial Fibrillation: Evidence And Opinion. AF, VKA
2021 Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre. ADCP, CATS, VTE
2021 Blood Coagulation Changes With or Without Direct Oral Anticoagulant Therapy Following Transcatheter Aortic Valve Implantation. FDP, SFMC, TAT, TAVI
10  2021 Budget Impact Analysis of Anticoagulation Clinics in Patients with Atrial Fibrillation under Chronic Therapy with Oral Anticoagulants. AC, NVAF, TTR, UC
11  2021 Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. CAT, LMWH
12  2021 Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. HIT, TE
13  2021 Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. ---
14  2021 Comprehensive Intraprocedural Unfractionated Heparin Protocol During Catheter Ablation of Atrial Fibrillation in the Presence of Direct Oral Anticoagulants and Wide Spectrum of Body Mass Index. ACT, BMI, CA-AF, UFH
15  2021 Direct oral anticoagulant reversal: An update. ---
16  2021 Direct oral anticoagulants and therapeutic adherence: do not let your guard down. VKA
17  2021 Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues. ---
18  2021 Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations. ---
19  2021 Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older. RCD, VKA, VTE
20  2021 Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. ---
21  2021 Effect of Antithrombotic Therapy on Secondary Bleeding After Proctological Surgery. ---
22  2021 Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis. AF, VKA
23  2021 Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis. ISTH, LMWH, OR, VKA, VTE
24  2021 Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. AF, PDC, SmartADHERE
25  2021 Entering the new ICE age with watchman FLX. AF
26  2021 Falls in ED patients: do elderly patients on direct oral anticoagulants bleed less than those on vitamin K antagonists? ED, VKA
27  2021 How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. ATVB
28  2021 Impact of Direct Oral Anticoagulant Off-Label Reduced Dose in Combination With Antiplatelet Agents on Clinical Outcome - Propensity Score-Matching Analysis From the DIRECT Real-World Non-Valvular Atrial Fibrillation Registry. AF, MACE
29  2021 Impending rupture of abdominal aortic aneurysm due to apixaban use. AAA, CT, ILT
30  2021 Isolated Radial Vein Thrombosis: Upper Extremity Deep Vein Thrombosis in a Patient With COVID-19 Infection. COVID-19, DVT, LMWH
31  2021 Limited benefit of systematic head CT for mild traumatic brain injury in patients under antithrombotic therapy. AC, AP, IH, mTBI
32  2021 Long-term oral anticoagulation for atrial fibrillation in low and middle income countries. AF, INR, LMICs, OAC, RHD, VKA
33  2021 Management of Patients Receiving Direct Oral Anticoagulants Scheduled for Radical Prostatectomy: An Update of a Prospective Assessment. DOACs, LMWH, RP
34  2021 Meta-analysis of direct oral anticoagulants compared with vitamin K antagonist for left ventricle thrombus. CI, LV, OR, VKA
35  2021 Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation. AF, ALM
36  2021 New-Onset Atrial Fibrillation and Multiple Systemic Emboli in a COVID-19 Patient. AF, COVID-19, DVT, LMWH, PE, SARS-CoV-2, VTE
37  2021 Outcomes in patients implanted with a Watchman device in relation to choice of anticoagulation and indication for implant. ---
38  2021 Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories. AF, BMI, CI, HRs
39  2021 Patient Perspectives on Factors Affecting Direct Oral Anticoagulant Use for Stroke Prevention in Atrial Fibrillation. AF
40  2021 Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users. SNVs
41  2021 Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban. HC-INR, HC-POCT, ROC
42  2021 Pre-injury use of antiplatelet and anticoagulations therapy are associated with increased mortality in a cohort of 1038 hip fracture patients. ---
43  2021 Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge. AF, GIB, MB, NGIB, OAC
44  2021 Prevalence of Frailty and Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation. NVAF, OAC, OR, OR, VA, VKA
45  2021 Relationship between the degree of renal dysfunction and the safety and efficacy outcomes in patients with atrial fibrillation receiving direct oral anticoagulants. AF, CrCl, MB, TEs
46  2021 Risk of over-anticoagulation during acute kidney injury in patients treated with vitamin K antagonists. AKI, INR, VKA
47  2021 Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin. AF, HRs, SAUB, VTE
48  2021 Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. aHR, ap, PPB
49  2021 Safety of catheter ablation of atrial fibrillation without pre- or peri-procedural imaging for the detection of left atrial thrombus in the era of uninterrupted anticoagulation. AF, TIA
50  2021 Short-term direct oral anticoagulation or dual antiplatelet therapy following left atrial appendage closure in patients with relative contraindications to chronic anticoagulation therapy. DAPT, DRT, LAAC, SAE
51  2021 Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation. AF
52  2021 The Effect of Direct Oral Anti-Coagulants on Delayed Traumatic Intracranial Hemorrhage After Mild Traumatic Brain Injury: A Systematic Review. mTBI, tICH
53  2021 The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis. Df, DVT, GP
54  2021 Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. AF, ETP, PCI, PPP, PRP, TG
55  2021 Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report. CA-PVT, CECT, POD
56  2021 Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005-2018. aORs, ICH, VKA
57  2021 Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: A systematic review and meta-analysis. AF, CA, RCT, RR, TE, TIA
58  2021 [Basics and Clinics of Cancer-Associated Venous Thromboembolism]. LMWH, VTE
59  2021 [Towards new indications for direct oral anticoagulants]. VTE
60  2021 [Use of antiplatelet therapy and direct oral anticoagulants in candidates for renal transplantation: The French guidelines from the CTAFU]. AT
61  2020 A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting. FXaIs, i-II-X, INR, PT
62  2020 A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus? 4F-PCCs, VKA
63  2020 A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation. AF
64  2020 A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations. IV UFH
65  2020 Acute Ischemic Stroke Outcome and Preceding Anticoagulation: Direct Oral Anticoagulants Versus Vitamin K Antagonists. AIS, OAC, VKA
66  2020 Acute Kidney Injury due to Anticoagulant-Related Nephropathy : A Suggestion for Therapy. ARN
67  2020 Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoagulation service. PDC, VTE
68  2020 Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. ADR, RI
69  2020 Anticoagulant therapy in cancer patients with atrial fibrillation. Considering age factor. AF
70  2020 Anticoagulant therapy with dual antiplatelet for left ventricular thrombus following acute myocardial infarction. DAPT
71  2020 Anticoagulant-related gastrointestinal bleeding: a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists. GIB, VKA
72  2020 Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy. COVID-19, ISTH, LMWH, UFH, VKA
73  2020 Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. AF, ICH, VKA, VTE
74  2020 Anticoagulation Strategies in the Management of Lemierre Syndrome: A Systematic Review of the Literature. LS
75  2020 Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry. APD, NVAF, OAT, VKA
76  2020 Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review. AF, VAF
77  2020 Anticoagulation therapy in cancer associated thromboembolism - new studies, new guidelines. CAT, LMWH
78  2020 Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. ---
79  2020 Anticoagulation-related nephropathy for the internist: a concise review. ARN, INR
80  2020 Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. MACCE, TT
81  2020 Antithrombotic Therapy of a Young Adult with Giant Left Main Coronary Artery Aneurysm. AMI, CAA, KD
82  2020 Applying population health approaches to improve safe anticoagulant use in the outpatient setting: the DOAC Dashboard multi-cohort implementation evaluation study protocol. EHR, RE-AIM, VHA
83  2020 Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation according to the drug labelling and the EHRA Practical Guide. DDIs, EHRA, NVAF, SmPC
84  2020 Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants? CAT, HOC, VTE
85  2020 Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study. AF, CIDs
86  2020 Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation. AF, HCPs, MMAS-8
87  2020 Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. ACS, CI, DAT, MACE, OR, TAT, VKA
88  2020 Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study. IHD, NVAF, PCI, VKAs
89  2020 Challenges of treatment adherence with direct oral anticoagulants in pandemic. COVID-19
90  2020 Characteristics and anticoagulant treatment status of elderly non-valvular atrial fibrillation patients with a history of catheter ablation in Japan: Subanalysis of the ANAFIE registry. AF, CA, Ccr, NVAF
91  2020 Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. AF
92  2020 Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings. ED, IP, OBS, VTE
93  2020 Clinical Trial Based Rationale for the Successful Use of DOAC in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A Case Report. CVST, VTE
94  2020 Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs. ACT, VKA
95  2020 Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians. ACS, AF, CAD, DAPT, INR, OACs, TIA
96  2020 Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. VTE
97  2020 Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis. CVT, VKA
98  2020 Contemporary Meta-Analysis of Extended Direct-Acting Oral Anticoagulant Thromboprophylaxis to Prevent Venous Thromboembolism. CI, OR
99  2020 Continued versus interrupted direct oral anticoagulation for cardiac electronic device implantation: A systematic review. CENTRAL, GRADE, RCTs
100  2020 Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. DOACs, ICER, QALYs, RCTs, VTE